303 related articles for article (PubMed ID: 29718432)
21. High frequency of H3 K27M mutations in adult midline gliomas.
Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
[TBL] [Abstract][Full Text] [Related]
22. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
23. Letter: Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System.
Lu VM; Alvi MA; Daniels DJ
Neurosurgery; 2018 Oct; 83(4):E193-E194. PubMed ID: 30379319
[No Abstract] [Full Text] [Related]
24. Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient.
Cheng R; Li DP; Zhang N; Zhang JY; Zhang D; Liu TT; Yang J; Ge M
Front Surg; 2021; 8():616334. PubMed ID: 34222313
[No Abstract] [Full Text] [Related]
25. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
26. Cerebellar high-grade glioma with H3 K27M mutation: illustrative case.
Takahashi M; Tomita Y; Yamada SM; Yamazaki K; Yokoo H; Aso T; Kawamoto M
J Neurosurg Case Lessons; 2021 Feb; 1(6):CASE20112. PubMed ID: 36045933
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.
Zhao B; Yao J; Wang J; Li J; Shi W; Zhang C; Zhao X; Qiao J; Ma Y; Xu Y; Zheng Z
Neurol Sci; 2024 Jun; 45(6):2845-2851. PubMed ID: 38228940
[TBL] [Abstract][Full Text] [Related]
28. In Reply: Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 WHO Health Organization Classification of the Central Nervous System.
Yi S; Choi S; Kim SH
Neurosurgery; 2018 Oct; 83(4):E195-E197. PubMed ID: 31222270
[No Abstract] [Full Text] [Related]
29. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
[TBL] [Abstract][Full Text] [Related]
30. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
31. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
32. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Low JT; Wang SH; B Peters K
CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
[TBL] [Abstract][Full Text] [Related]
33. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
34. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
J Neurosurg Spine; 2022 Feb; 36(2):303-314. PubMed ID: 34560639
[TBL] [Abstract][Full Text] [Related]
35. Pediatric ganglioglioma with an H3 K27M mutation arising from the cervical spinal cord.
Okuda T; Hata N; Suzuki SO; Yoshimoto K; Arimura K; Amemiya T; Akagi Y; Kuga D; Oba U; Koga Y; Ohga S; Iwaki T; Iihara K
Neuropathology; 2018 Apr; ():. PubMed ID: 29675936
[TBL] [Abstract][Full Text] [Related]
36. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
[TBL] [Abstract][Full Text] [Related]
37. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
Kleinschmidt-DeMasters BK; Mulcahy Levy JM
Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
[TBL] [Abstract][Full Text] [Related]
38. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics and survival of spinal cord astrocytomas.
Zhang YW; Chai RC; Cao R; Jiang WJ; Liu WH; Xu YL; Yang J; Wang YZ; Jia WQ
Cancer Med; 2020 Oct; 9(19):6996-7006. PubMed ID: 32777166
[TBL] [Abstract][Full Text] [Related]
40. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
